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INTRODUCTION 
Drug delivery is a vital aspect of formulat ion as its proper 
choice controls the bioavailability, concentration profile 
and side effects (by targeted drug delivery)
 1. 
While the 
most compliant way of drug administration might be its 
oral, it requires that drug is stable in conditions for 
example: pH, enzyme activ ity, epithelial permeability. 
Example, Insulin- peptide drug will be normally degraded 
by the digestive enzymes
1
. Thus, a suitable drug delivery 
system would protect the drug against degradation and 
ensure that drug reaches proper permeability properties 
and further provides a combined transportation and 
protection system against the natural barriers, as done by 
the dendrimers
1
. Dendrimers are highly defined 
nanoparticles: 
– Size: 1 -15 nanometers  
– Very versatile  surface functionalisation 
– Synthetic: Pract ical and cost effective  
– Well tolerated pharmaceutica  
 
What is a dendrimer?  
Dendrimer is a nanoparticle (10
-9
) and so has advantages 
over microparticles or others due to its small size, easy 
uptake by cells (through endocytosis)
1
. They are branched 
macromolecules have a central core unit having a high 
degree of molecular uniformity, narrow molecu lar weight, 
distribution, specific size and shape characteristics, and a 
highly- functionalized, terminal surface. The 
manufacturing process is a series of repetitive steps  
 
generating shells, starting with a central initiator core. 
Each subsequent shell represents a new "generation" of 
polymer with a larger molecular diameter, twice the 
number  
of reactive surface sites, and approximately double the 
molecular weight of the preceding generation
2
. Dendrimers 
have cellular uptake through endocytosis and thus brings 
drug „bound‟ to dendrimers into the cell1. 
Goals:  
A) Modify/Improve the pharmacokinetic and 
pharmacodynamic properties of a drug so that there is also 
an accretion in bioavailability. 
B) Achieve the controlled and targeted release of drug 
restricted to the area desired. 
Expectations: 
The reduced size provides increased surface area to 
volume ratio properties
3
: 
A) Optical properties, e.g. fluorescence, become a function 
of the particle d iameter (control in size).  
B) When brought into a bulk material, nanoparticles can 
strongly influence the mechanical properties, such as 
rig idity and strength. 
Example, trad itional polymers can be rein forced by 
nanoparticles resulting in novel materials ; e.g. as light 
weight replacements for metals. Therefore, an increasing 
societal benefit of such nanoparticles can be expected.  
 
 
ABSTRACT 
Dendrimer as a drug delivery agent is a promising, safe and selective drug delivery option. It‟s highly selective nature 
for targeting the desired tissue is the most essential property and holds a promising future for the treatment of several 
disorders. Its other properties like very small size, polyvalency, monodispersity, stability make it an appropriate 
carrier for delivering drugs with precision and selectivity.  Dendrimers are being used as dru g delivery systems for 
various drugs like anticancer drugs (methotrexate), drug for prevention of HIV, enhancing bioavailability of 
pilocarpine for ocular drug delivery, et al. Dendrimer as a drug delivery system is based on the approach of sending a 
nanoparticle   (10-9) to the body, loaded with drug. The drug might be loaded on its terminal surface or encapsulated 
within the branches of a dendrimer. Dendrimers help in achieving increased bioavailability, sustained, controlled as 
well as targeted release of drug. There is reduction in the amount of drug and systemic toxicity while the therapeutic 
efficacy increases. This approach as a drug delivery system certainly promises a reliable, safe, selective and precise 
method of drug delivery. Thus present review focuses on the fundamentals of dendrimers and their use as drug 
delivery agents in treatment of disorders. 
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Table 1: Generation and corresponding structure of dendrimers
4
 
Generation of dendrimers Structure 
First three Small, not specific three dimensional structure 
Fourth (G4) Beginning to become spherical, to a preferred three dimensional structure 
Fifth (G5) Highly structured spheres 
 
 
Figure 1: Sturcture of a Dendrimer  
 
SYNTHES IS OF DENDRIMER  
First two are the Main two methods for synthesis of 
dendrimers- 
A) Divergent growth method (introduced by Tomalia )4 
Growth of dendrimers originates from a core site. 
Process is repeated until the dendrimer of the 
described size is obtained 
B) Convergent growth method18- begins at what will 
end up being the surface of the dendrimer and works 
inwards by gradually linking surface units together 
with more. When the growing wedges are large 
enough, several are attached to a suitable core to give 
a complete dendrimer. 
An advantage of convergent growth over divergent 
growth stem: Two simultaneous reactions are 
required for any generation-adding step
5
. 
C) Hypercores’ and ‘Branched Monomers’ growth - 
Linkage of the oligomeric species in a radial, branch-
upon-branch.  Core is reacted with two or more 
moles of reagent containing at least two protecting 
branching sites, followed by removal of the 
protecting groups. The subsequent liberated reactive 
sites lead to the first generation dendrimers
6
 
D) Double Exponential’ growth- monomers are 
prepared from a single starting for divergent and 
convergent growth. Resulted two products reacted to 
give orthogonally protected trimer, which can be 
used to repeat the growth again
6
. 
 
MECHANIS M OF DRUG DELIVERY THROUGH 
DENDRIMERS : 
The well defined 3D structure and many functional surface 
groups, drug molecules can be loaded both in the interior 
of the dendrimers as well as attached to the surface groups 
( as shown in the figure). Dendrimers can function as drug 
carriers either by encapsulating drugs within the dendritic  
structure, or by inter-acting with drugs at their terminal 
functional groups via electrostatic or covalent bonds 
(prodrug)
 2, 7, 8
. 
There are broadly two mechanisms for drug delivery.  
A) First, is by in vivo degradation of drug dendrimer 
conjugate (covalent bonding of drug to dendrimer), which  
depends on presence of suitable enzymes or an 
environment capable of degrading bonds. 
B) The second one is by releasing the drug due to changes 
in physical environment such as pH, temperature. Th is 
approach is independent of the external factors and takes 
place in cavities of the core (endo-receptor) or outer shell 
of receptor (exo -receptor) 
1
. 
 
Figure 2: A Dendrimer molecule with drug molecules loaded at  
terminal surface of branches 
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Figure 3: A Dendrimer molecule with drug molecules encapsulated 
within branches. 
There are two types of delivery, one is to a specific type of 
cell and other as a controlled release from a depot (which  
may be present in circulation or imbedded in some suitable 
tissue) 
1
.
 
Psividas biosilicon allows drug molecules to be 
held in nano-sized part icles that release a t iny pulse of 
drug as the biosilicon dissolves. Biosilicon shows 
resistance to degradation in acid environment
3
.
 
FUNCTIONAL COMPONENT: 
A dendrimer of higher generations consists of shell. A 
shell consists of a central core and alternating two layers of 
monomers around it. Amines constitute the central core 
which may sometimes be replaced by sugar. All core 
molecules have multiple and identical reaction site. Amine 
is the simplest core molecule present with three functional 
sites. The surface of all full generations consists of 
multip le amines, while the surface of the half generations 
consists of multiple acids. These two kinds of surfaces 
provide the means of attachment of multiple different 
functional components  
9
. 
PROPERTIES  OF DENDRIMER: 
A) Monodis persity- well-defined molecular structure 
thus workable for a scalable size. 
B) Nanoscale size and shape- The small size has a lot 
of advantages discussed later. 
C) Polyvalency- i.e. the functional/reactive groups on 
the dendrimer structure. This responsible for more 
interactions between surfaces and bulk materials  
(adhesives, surface coatings, or polymer cross -
linking) 
6
. Example:  topical vaginal microbicide 
called Vivagel 
D) Adaptive nature of dendrimers: Dendrimers can 
adapt “native” (e.g. tighter) or “denaturated” (e.g. 
extended) conformat ions dependent on the polarity, 
ionic strength and pH of the solvent 
6
.
Table 2: Properties of Dendrimer and linear polymers 
Sr. 
No. 
Property Dendrimers  Linear Polymers  
1 Structure Compact, Globular Not compact  
2 Synthesis Careful & stepwise growth Single step polycondensation 
3 Structural control Very high  Low 
4 Architecture Regular Irregular 
5 Shape Spherical Random coil 
6 Crystallan ity Non-crystalline, amorphous materials  
-lower g lass temperatures 
Semi crystalline/crystalline materials 
-Higher glass temperatures  
7 Aqueous solubility High  Low 
8 Non-polar solubility  High  Low 
9 Viscosity Non linear relationship with molecular weight Linear relat ion with molecular weight  
10 Reactivity  High  Low 
11 Compressibility Low High  
12 Polydispersity Monodisperse Polydisperse 
 
IDEAL BIOCOMPATIBILITY PROPERTIES: 
A) Nontoxic, 
B) Non-immunogenic, biopermeable  
C) Able to stay in circu lation for the time needed to have a 
clin ical effect. 
D) Able to target specific structures 
ADVANTAGES  OF DENDRIMER DRUG 
DELIVERY:-
 
 
A) Medication to the affected part inside a patient's body 
directly 
10
. 
B) In target drug delivery: Dendrimers are suitable for 
targeting solid tumours due to increased permeability, 
limited drainage in tumour vasculature which will lead to 
accumulat ion of macromolecules in tumour
 1 
(enhanced 
permeat ion  rate). There is also reduction in amount of 
drug used via targeted delivery (attaching site specific 
ligands at surface or magnetic guidance) 
11
 and thus 
reduction in systemic toxicity 
C) Controlled and sustained release of drugs can also be 
obtained. 
D) Drugs can be easily made to remain within  layers of 
skin and not penetrate in systemic circulation  
E) Bypassing the gastric medium and hence the eschewing 
the variation due to effect of gastric secretions. 
F) Increase in therapeutic efficacy, decrease in side effects: 
decreased clearance of drug via altered distribution of drug 
in organs at site of localization and transportation due to 
controlled and sustained release of the drug
9
. 
G) Relatively high drug loading.  
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H) Preservation of drug activity: as drugs can be 
incorporated into the systems without any chemical 
reaction. 
I) Limitations of other nanoparticles  overcome; for 
example: overcoming limitations of liposomes like: 
1. low encapsulation efficiency 
2.  rapid leakage of water-soluble drug in presence 
of blood components 
3.  Poor storage stability  
CHARACTERIZATION OF DENDRITIC POLYMERS 
Following methods can be used for characterization of 
dendritic polymers. 
1. S pectroscopy and s pectrometry methods  like Nuclear 
Magnetic Resonance (NMR), Infra-red (IR) and Raman, 
Ultra-vio let-visible (UV-VIS), Fluorescence, Chirality, 
Optical rotation, Circular d ichrois m (CD), X-ray  
diffraction, and Mass spectrometry  
2. Scattering techniques  like Small angle X-ray scattering 
(SAXS), Small angle neutron scattering (SANS), and 
Laser light scattering (LLS) 
3. Electrical techniques  like Electron paramagnetic 
resonance (EPR), Electrochemistry, and Electrophoresis 
4. Size exclusion chromatography (SEC) 
5. Microscopy like Transmission electron microscopy, 
Scanning electron microscopy and atomic force 
microscopy 
6. Rheology, physical properties  like intrinsic v iscosity, 
Differential Scanning Calorimetry (DSC), and Dielectric 
spectroscopy (DS) 
7. Miscellaneous  like X-ray Photoelectron Spectroscopy 
(XPS), measurements of dipole moments, titrimetry, etc.  
APPLICATIONS OF DENDRIMERS IN DRUG 
DELIVERY:  
A) Various routes for dendrimer drug delivery:  oral,  
parenteral, intra-ocular, nasal 
B) Gene therapy, immunodiagnostics: Dendrimers 
can act as vectors , in gene therapy. PAMAM 
dendrimers have been tested as genetic material 
carriers. Numerous reports have been published 
describing the use of amino-terminated PAMAM or 
PPI dendrimers as non-viral gene transfer agents, 
enhancing the transfection of DNA by endocytosis 
and, ultimately, into the cell nucleus
12
. 
C) Dendrimer in ocular drug  delivery- to enhance 
pilocarpine b ioavailab ility. 
D) Dendrimers in pulmonary drug delivery- for 
Enoxaparin (40% increase in relative bioavailability 
by G2 and G3 generation positively charged 
PAMAM dendrimers)
 6
. 
E) Dendrimer in transdermal drug delivery- 
improvement in solubility and plasma circulat ion 
time. PAMAM dendrimer complex with NSAIDs as 
permeat ion enhancers
6
. 
F) Dendrimers for controlled release drug delivery- 
anticancer drugs like methotrexate, adriamycin. 
Some of the methods to initiate the release include 
light, removal of protecting groups, and antibodies 
13
. 
Dendrimers have attracted attention as possible drug 
carriers because of their unique properties namely  
their well deﬁned three-dimensional structure, the 
availability of many functional surface groups, their 
low po lydispersity and their ability to mimic. Drug 
molecules can be loaded both in the interior of the 
dendrimers as well as attached to the surface groups. 
Dendrimers can function as drug carriers either by 
encapsulating drugs within the dendritic structure, or 
by inter-acting with drugs at their terminal functional 
groups via electrostatic or covalent bonds 
(prodrug).
12, 14, 15
 
G) Dendrimers in targeted drug delivery- folic acid  
PAMAM dendrimers modified with carboxymethyl 
PEG5000 surface chains
 6
. 
H) Dendrimers As Nano-Drugs12: 
Poly(lysine) dendrimers modified with sulfonated 
naphthyl groups have been found to be useful as 
antiviral drugs against the herpes simplex virus can 
potentially prevent/reduce transmission of HIV and 
other sexually transmitted diseases (STDs)
 12
. 
I) Dendrimers In Photodynamic Therapy 12, 15: The 
photosensitizer 5-aminolevulinic acid  has been 
attached to the surface of dendrimers and studied as 
an agent for PDT of tumorigenic keratinocytes 
.Photos ensitive dyes have been incorporated into 
dendrimers and utilized in PDT devices (10). This 
cancer treatment involves the admin istration of a 
light- activated photosensitizing drug that selectively 
concentrates in diseased tissue. 
 
DENDRIMER BAS ED PRODUCTS 
6
: 
A)  VIVAGELTM (Starpharma): In clin ical phase II 
trials, it ‟s  a topical vaginal microb icide, prevents 
infection by HIV (polyvalent properties).  
B) Stratus® CS Acute Care TM (Dade Behring) - for 
cardiac diagnostic testing
6
. 
C) SuperFectTM (Qiagen) - gene transfection agent 
applicable to a broad range of cell lines  
CYTOTOXICITY ISS UES  REPORTED IN VIVO
 6
: 
A) Dendrimers with positively charged surface groups -
prone to destabilize cell membranes and cause cell lysis. 
B) Generat ion dependent toxicity-higher generation 
dendrimers being the most toxic. 
C) Degree of substitution, type of amine functionality is 
important- primary amines being more toxic than 
secondary or tertiary amines.
 
CONCLUS ION 
Dendrimers are promising in  solutions against poor 
solubility, b ioavailab ility, permeability, d iagnostic and 
many other fields of pharmaceutical applications, thus, 
dendrimers holds a promising future in drug delivery. The 
risks can be eliminated with proper choice of carrier. 
Dendrimers, due to its superior architecture; high level of 
branching, multivalency, globular architecture and 
molecular weight, prove to be a novel and reliable method 
of drug delivery. The rev iew clearly illustrates the different 
aspects of dendrimers as novel drug delivery system and 
there will be accretion in the dendrimers seen as drug 
delivery systems with the advent of more and more 
dendrimers used for it.  
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